

## Subject Review

## Mechanisms of Motility in Metastasizing Cells

Mahmut Yilmaz and Gerhard Christofori

## Abstract

Cell migration and invasion are critical parameters in the metastatic dissemination of cancer cells and the formation of metastasis, the major cause of death in cancer patients. Migratory cancer cells undergo dramatic molecular and cellular changes by remodeling their cell-cell and cell-matrix adhesion and their actin cytoskeleton, molecular processes that involve the activity of various signaling networks. Although in the past years, we have substantially expanded our knowledge on the cellular and molecular processes underlying cell migration and invasion in experimental systems, we still lack a clear understanding of how cancer cells disseminate in metastatic cancer patients. Different types of cancer cell migration seem to exist, including single-cell mesenchymal or amoeboid migration and collective cell migration. In most epithelial cancers, loss of the cell-cell adhesion molecule E-cadherin and gain of mesenchymal markers and promigratory signals underlie the conversion of epithelial, differentiated cells to mesenchymal, migratory, and invasive cells, a process referred to as the epithelial-to-mesenchymal transition. Although solitary migrating epithelial cancer cells have mostly undergone epithelial-to-mesenchymal transition (mesenchymal migration), and sometimes even lose their cell-matrix adhesion (amoeboid migration), collective migration of cancer cells in cell sheets, clusters, or streams is also frequently observed. The molecular mechanisms defining the different modes of cancer cell migration remain in most parts to be delineated. *Mol Cancer Res*; 8(5): 629–42. ©2010 AACR.

Despite major efforts in metastasis research, we still lack detailed insights into how cancer cells actually migrate out of primary tumors and invade into neighboring tissue, how they enter (intravasate) into the blood or the lymphatic circulation, how they survive “homelessness” and immune surveillance in the bloodstream, and how they target certain organs to leave (extravasate) the blood circulation and to initiate metastatic outgrowth in specific target organs. Obviously, the migratory and invasive capabilities of a cancer cell present critical parameters in the metastatic cascade. Plenty of molecular pathways define distinct types of migration and invasion in a cancer cell–autonomous manner, including single-cell amoeboid and mesenchymal migration and collective cell migration (1, 2). In many instances, stromal cells, such as blood vessel and lymphatic endothelial cells, cancer-associated fibroblasts, or bone marrow–derived inflammatory cells, act as modulators of cancer cell migration and invasion and as pathfinders in the extracellular matrix (3). Moreover, chemokine gradients within the tumor microenvironment or in the blood and lymphatic system, as well as the establishment of an appropriate “metastatic niche” in future metastatic organs,

contribute to the targeted colonization of distant organs (4). In this review, we present various concepts on the signaling pathways and molecular mechanisms underlying the onset of cancer cell migration and invasion during tumor progression and metastasis. The molecular details of actin cytoskeleton remodeling and changes in cell-substrate adhesion during cell migration and invasion have been recently summarized in several excellent reviews (5–11).

## Loss of Cell-Cell Adhesion

To leave the primary tumor and to invade into the surrounding tissue, tumor cells dissolve their cell-cell contacts; adjust their cell-matrix adhesion sites to a more transient, migratory, and invasive mode; and follow a chemoattractive path through the extracellular matrix, often facilitated by secreted proteinases. Similar to developmental processes like gastrulation or neural crest cell migration, differentiated epithelial tumor cells lose their epithelial morphology and migrate to a distant site to form a new structure, in this case secondary tumors. Such temporary and reversible phenomenon is known as epithelial-to-mesenchymal transition (EMT), a process that is currently a major focus in metastasis research (12–14). The actual occurrence of EMT in patients is still debated; however, with more detailed molecular and histopathologic analysis and the discovery of novel markers, there is increasing evidence for EMT in various human cancers (15–17). However, cancer cells can also migrate and invade in the absence of EMT and may use a broad repertoire of cell migration and invasion (18, 19).

**Authors' Affiliation:** Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland

**Corresponding Author:** Gerhard Christofori, Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland. Phone: 41-61-267-3562; Fax: 41-61-267-3566. E-mail: gerhard.christofori@unibas.ch

doi: 10.1158/1541-7786.MCR-10-0139

©2010 American Association for Cancer Research.




miR-200 family have been specifically shown to play an important role in TGF $\beta$ -induced EMT by regulating the production of ZEB1 and ZEB2 (38-42). Binding of the transcriptional repressors to the E-cadherin gene promoter eventually leads to epigenetic silencing of the gene in a multistage process (43). First, Snail1 recruits a histone deacetylase to the E-cadherin promoter complex, thereby inducing histone deacetylation. Subsequently, polycomb repressor complex 2 (PRC2) is drafted to modify histones by methylation. Snail1 also induces expression of ZEB1, which in turn engages a second, PRC2-independent repressor complex that further inhibits E-cadherin expression. In addition, new interaction partners of Snail1 have been identified, such as the LIM-domain protein Ajuba, which recruits arginine methyltransferase 5 (PRMT5) to support Snail1-mediated transcriptional repression (44). Yet, how the initial silencing of the E-cadherin gene promoter converts into a long-term repression by DNA hypermethylation remains to be resolved (45). During TGF $\beta$ -induced EMT of mammary gland cells, a decrease in active histone modifications (H3K9Ac and H3K4me3) and an increase in the repressive histone modification H3K27me3 has been observed concomitant with an increase in DNA methylation of the E-cadherin and the  $\alpha_4$  integrin promoters (46). Notably, TGF $\beta$  withdrawal promotes a reversion of EMT and triggers the reexpression of E-cadherin and  $\alpha_4$ -integrin in the absence of a loss of promoter DNA hypermethylation, whereas both H3K9Ac and H3K4me3 modifications are restored and H3K27me3 is reduced, suggesting a dominance of histone modification over DNA methylation in epigenetic control of the E-cadherin and  $\alpha_4$ -integrin genes. Finally, E-cadherin expression is also directly repressed by miRNA-9, which is found upregulated in breast cancer cells (47).

E-cadherin function can also be impaired by preventing its transport to the plasma membrane through O-glycosylation (48) or by proteolytic cleavage or endocytosis from the plasma membrane (49-52). Proteolytic cleavage of E-cadherin can generate E-cadherin fragments that exert signaling functions. For example, the shedded extracellular domain of E-cadherin has been shown to interfere with epithelial cell-cell adhesion and to induce cell migration (53). Moreover,  $\gamma$ -secretase-mediated cleavage produces a COOH-terminal, cytoplasmic fragment (CTF2) of E-cadherin that is imported into the nucleus, where it modulates the interaction between p120-catenin and Kaiso, a transcriptional repressor, and thus impinges on gene expression (ref. 54; Fig. 1). E-cadherin-mediated cell adhesion complexes can also be disassembled through phosphorylation of E-cadherin or  $\beta$ -catenin by receptor tyrosine kinases or by the non-receptor tyrosine kinase Src, resulting in E-cadherin endocytosis, ubiquitylation by the E3 ubiquitin ligase Hakai, and subsequent proteasomal degradation (refs. 55, 56; Fig. 1B). Moreover, focal adhesion kinase activated by integrin-mediated cell-matrix adhesion may also phosphorylate  $\beta$ -catenin and thus induce its ubiquitylation and degradation and the disassembly of the E-cadherin cell adhesion complex (57).

E-cadherin can be endocytosed through clathrin or caveolin-dependent mechanisms (58-60). For example, EGFR-stimulated invasion of epithelial cells relies on endocytosis of E-cadherin, which involves the activities of the GTPase Arf6 and the Arf6 guanine nucleotide exchange factor (GEF) GEP100 (61). On EGFR activation, GEP100 binds to specific phosphotyrosine residues of EGFR and then activates Arf6 localized in cell-cell adhesions, which in turn induces E-cadherin endocytosis. Notably, the activated GEP100/Arf6 complex is also critical in the regulation of cell-matrix adhesion and cell migration by stimulating the recycling of  $\beta_1$ -integrin (62). Conversely, the Arf6-specific GTPase-activating protein (GAP) Smap1 has been shown to counteract E-cadherin endocytosis (63).

Loss of E-cadherin function leads to a disruption of adherens and tight junctions and the loss of cell polarity, and also liberates proteins from the cytoplasmic cell adhesion complex. Besides its critical role in assembling the E-cadherin-mediated cell adhesion complex,  $\beta$ -catenin (and also  $\gamma$ -catenin) plays an important role in canonical Wnt signaling. Upon loss of E-cadherin function, liberated  $\beta$ -catenin is rapidly phosphorylated by glycogen-synthase kinase 3 $\beta$  (GSK3 $\beta$ ) in the adenomatous polyposis coli (APC)/axin/GSK3 $\beta$  complex and subsequently degraded by the ubiquitin-proteasome pathway (ref. 64; Fig. 2A). If the tumor suppressor APC is nonfunctional, as is the case in many cancer cells, or if GSK3 $\beta$  is repressed by an activated Wnt signaling pathway,  $\beta$ -catenin accumulates at high levels in the cytoplasm. Subsequently, it translocates to the nucleus, where it binds to members of the Tcf family of transcription factors and modulates the expression of target genes implicated in cell proliferation, transformation, and tumor progression, such as c-Myc, cyclin D1 and D2, fibronectin, matrix metalloproteinase 7 (MMP-7), Id2, CD44, axin-2, Tcf-1, the cell adhesion molecule L1-CAM, the metastasis gene S100A4, and others (65-67). Another recently discovered target of  $\beta$ -catenin/Tcf signaling is fascin, an actin-bundling protein that is essential for filopodia formation and cancer cell invasion (68). In fact, fascin and L1-CAM are expressed in cells of the invading front of colorectal cancers that also exhibit nuclear  $\beta$ -catenin (69, 70). However, such activation of  $\beta$ -catenin/Wnt signaling by the loss of E-cadherin function seems to depend on cell context and the mutational status of the components of the Wnt signaling pathway, and thus is found active in some but not all cancer types (25, 47, 71).

The juxtamembrane domain of E-cadherin binds to p120-catenin, which is important for the correct membrane localization of E-cadherin (72-75). Similar to  $\beta$ -catenin, upon loss of E-cadherin function, p120-catenin is also liberated from the cytoplasmic cell adhesion complex and accumulates in the cytoplasm (Fig. 2B). There, p120-catenin represses the activity of RhoA and activates Rac and Cdc42 (76-78). All three GTPases are key regulators of actin assembly and play an essential role in the stability of cell-cell adhesion and the induction of cell migration by enforcing actin stress fibers (RhoA) and the formation of migratory membrane protrusions, such as



lamellipodia and filopodia (Rac and Cdc42, respectively; Fig. 2B, see below). p120-catenin also interacts with cortactin and interferes with Arp2/3-dependent cortical actin and stress fiber polymerization (79).

On the other hand, liberated p120-catenin can traffic to the nucleus where it binds the transcriptional repressor Kaiso. In contrast to  $\beta$ -catenin/Tcf-mediated transcription, where  $\beta$ -catenin acts as a transactivator, p120-catenin has no transactivation domain and rather releases Kaiso from its promoter binding sites and thus activates gene expression by derepression (ref. 80; Fig. 2B). Kaiso seems to bind to Tcf/ $\beta$ -catenin target genes and to hypermethylated tumor suppressor genes; however, p120/Kaiso target genes are still poorly defined (81).

### The Cadherin Switch and Cell Migration

In most epithelial cancers, the loss of E-cadherin function during tumor progression results in an increased expression of the mesenchymal cadherin, N-cadherin (and sometimes other mesenchymal cadherins), with a drastic change in the adhesive properties of cancer cells, as they lose their affinity for epithelial neighbors and gain affinity for stromal cells. The cadherin switch by itself seems to provoke cell migration and invasion (82, 83) and correlates with poor prognosis (83-85). During the cadherin switch upon loss of E-cadherin function, the transcriptional repressor Twist seems to be critical for the induction of N-cadherin (and also fibronectin) gene expression (86, 87).


Similar to E-cadherin, N-cadherin also exerts both cell-cell adhesion and signaling functions that seem to be mechanically linked. For example, traction forces generated by retrograde actin flow during neurite extension directly modulate N-cadherin-mediated cell adhesion (88). The mechanical engagement of N-cadherin induces local actin polymerization and ensures the integrity of the cell adhesion complex. On the other hand, N-cadherin interacts with various growth factor receptors and modulates signal transduction (Fig. 3A). For example, by binding both  $\beta$ -catenin in the N-cadherin/ $\beta$ -catenin cytoplasmic cell adhesion complex and platelet-derived growth factor receptor (PDGFR),  $\text{Na}^+/\text{H}^+$  exchanger regulatory factor-2 has been shown to physically link N-cadherin to PDGFR (89). PDGFR activation, in return, is known to induce actin reorganization, cell proliferation, differentiation, and migration (90, 91). Interestingly, PDGF stimulation of

NIH3T3 cells leads to the colocalization of N-cadherin, p120-catenin, and p190RhoGAP in dorsal circular ruffles, structures known to depend on growth factor-mediated Rac activation and RhoA inhibition (92-94). Apparently, p120-catenin together with p190RhoGAP coordinates the antagonistic functions of Rac and RhoA, which plays a critical role in defining the structure of the actin cytoskeleton (refs. 76, 95; Fig. 2B). The active form of RhoA stimulates focal adhesion formation and contractility through assembly of predominantly radially oriented actin stress fibers, whereas Rac activation induces cell spreading, cell migration, and membrane ruffling through actin polymerization at the cell periphery. Moreover, Rac activation inhibits Rho activity, which can also be achieved by p120-catenin overexpression (96).

N-cadherin also interacts with fibroblast growth factor receptors (FGFR; Fig. 3A). The interaction between N-cadherin and FGFR prevents the internalization of FGFR upon FGF binding and results in a sustained mitogen-activated protein kinase (MAPK) pathway activation together with increased cell motility, MMP secretion, and invasiveness (97-99). A similar stimulation of FGFR is also observed with neural cell adhesion molecule (NCAM), an immunoglobulin domain cell adhesion molecule (100). NCAM achieves a similar stimulation of cell migration and invasion by directly binding and activating FGFR through its fibronectin type III domains (ref. 100; Fig. 3B). NCAM-mediated activation of FGFR signaling differs substantially from FGF-induced FGFR signal transduction: NCAM maintains high FGFR signaling by preventing receptor endocytosis and provokes increased cell-substrate adhesion, cell migration, and invasion, whereas FGF predominantly induces a short-lived FGFR signal and mainly promotes cell proliferation (101, 102). Notably, NCAM is one of the first genes upregulated during EMT in a number of cancer types, and, in these cancer cells, it is required for cell adhesion, migration, and invasion (ref. 24; Fig. 3B).

Proteolytic processing of N-cadherin also generates shedded extracellular domain fragments and intracellular fragments with potential signaling functions (Fig. 3A). In neurons, bone morphogenic protein-4 provokes cleavage of N-cadherin by ADAM10 and by PS1/ $\gamma$  secretase to produce a cytoplasmic fragment of N-cadherin, N-Cad/CTF2 (refs. 103, 104; Fig. 3A). N-Cad/CTF2 is able to bind the transcription factor cAMP-responsive element binding

**FIGURE 2.** Signals downstream of loss of E-cadherin. Schematic view of the signaling pathways and molecular processes mediating cell migration and invasion upon loss of E-cadherin function. A, following the loss of E-cadherin function, for example, by RTK-mediated signaling and phosphorylation of E-cadherin or catenins, catenins are released and may accumulate in the cytoplasm. Cytoplasmic  $\beta$ -catenin is sequestered by the APC/axin/GSK3 $\beta$  complex, phosphorylated by GSK3 $\beta$ , ubiquitinated by the E3 ligase  $\beta$ TrCP, and thereby earmarked for rapid proteosomal degradation. However, upon activation of the Wnt signaling pathway, GSK3 $\beta$  is repressed and  $\beta$ -catenin is no longer phosphorylated. It translocates to the nucleus, where, together with Tcf-family transcription factors, it modulates expression of a number of target genes known to be involved in cell proliferation and tumor progression. B, displacement of p120 catenin, as well as the activity of IQGAP1, results in the modulation of the activity of Rho-family GTPases. Upon loss of E-cadherin function, cytoplasmic p120-catenin acts as a GDI and represses RhoA and thus stress fiber formation, whereas it activates Rac1 and Cdc42 through the GEF Vav2 and thereby induces the formation of lamellipodia and filopodia, respectively. Rac1 and Cdc42, in turn, repress RhoA activity through the GAP 190RhoGAP and inhibit IQGAP1 by binding to it. Together, these activities induce reorganization of the actin cytoskeleton and the migratory behavior of tumor cells (see text for details).



protein (CREB)-binding protein (CBP) and to induce its proteasomal degradation. The subsequent repression of CPB/CREB-mediated transcriptional control stifles expression of genes important for proliferation and differentiation, such as *c-Fos*. N-Cad/CTF2 has also been shown to promote migration of neural crest cells by increasing the expression of  $\beta$ -catenin and its target genes (105). However, the actual contribution of N-cadherin processing to tumor invasion and metastasis still needs to be determined.

### Single-Cell Migration

Cell migration can be classified into single-cell migration (amoeboid or mesenchymal, solitary, or in indian files) or collective cell migration (in cell sheets, strands, tubes, or clusters; refs. 1, 106). Differences in extracellular protease activities, integrin-mediated cell-matrix adhesion, cadherin-mediated cell-cell adhesion, cell polarity, and cytoskeletal arrangement define the type of cell migration and invasion. Finally, stromal cells may contribute to the different types of migration, such as stromal fibroblast leader cells in collective cell migration and macrophage pioneer cells in single-cell migration. In morphogenic processes during embryonic development, single-cell migration or indian file–like invasion of cells in most cases involves the loss of epithelial polarity and the gain of mesenchymal morphology during EMT. Examples are neural crest cells leaving the neural tube or migrating limb muscle precursor cells.

In cancer, the various types of cell migration can be found with different degrees and combinations. For example, colorectal cancer cells that have lost E-cadherin expression disseminate as solitary, actively migrating cells, and, once arrived at their destination organ, redifferentiate to form secondary tumors with a phenotype comparable with the primary tumor. In contrast, squamous cell carcinomas invade predominantly in a collective type of cell migration (see below). Cancer cells in most parts use morphogenic developmental programs to control their migratory and invasive capabilities. These processes involve a dramatic reorganization of the actin cytoskeleton and the concomitant formation of membrane protrusions required for cell motility in a complex three-dimensional environment, including lamellipodia, filopodia, podosomes, and invadopodia (5, 6, 8, 107).

Members of the Rho GTPase family play a pivotal role in transmitting signals from growth factor and cell adhesion receptors to effector proteins of actin cytoskeleton remodeling (10, 108-110). RhoGTPases are activated upon GTP binding and inactive in their GDP-bound form. RhoGTPase activation is tightly controlled by GEFs, GAPs, and guanine nucleotide dissociation inhibitors (GDI). GEFs activate RhoGTPases by promoting the exchange of Rho-bound GDP by GTP. This is counteracted by GAPs that raise the intrinsic GTPase activity of RhoGTPases and the hydrolysis of bound GTP to GDP. Finally, GDIs bind inactive Rho-GDP and prevent their interaction with RhoGEFs, and thus, activation.

RhoA, Rac1, and Cdc42 are the best studied members of the RhoGTPase family, and their critical role in cell migration and invasion has been repeatedly shown (10, 109-111). In the GTP-bound form, RhoGTPases activate downstream effector proteins. These include for Rac1 the serine/threonine kinases p21-activated kinases (PAK1-3) and myosin light chain kinase; for Cdc42, PAK1-6, WASP, N-WASP, and mDia2; and for RhoA, the ROCK kinases I and II, Citron, and mDia1 and mDia2. It should be noted that RhoGTPases are critical for many biological processes in a cell's life, not only for cell migration and invasion but also for cell proliferation and survival (110, 112, 113). With regard to cell migration and invasion, RhoA induces actin stress fiber formation and regulates cytoskeletal configurations affecting cell-cell or cell-matrix adhesion. Conversely, Rac1 is involved in lamellipodia and membrane ruffle formation, and Cdc42 excites filopodia formation (114, 115). Based on their central function in actin remodeling and their ability to activate MMP, RhoGTPases play an important role in tumor cell invasion and metastasis (116). Novel imaging technologies to visualize the homeostasis of adherens junctions and the activities of RhoGTPases in live cells in a temporal and spatial manner have provided exciting new insights into the tight control of actin cytoskeleton assembly and disassembly during cell migration (117, 118). For example, experiments using fluorescence resonance energy transfer probes for RhoA activity in live cells have revealed that RhoA activity is found not only at the retracting tail of a migrating cell, as has been previously assumed, but also at the leading edge (93).

**FIGURE 3.** The contribution of N-cadherin and NCAM to cancer cell migration. Schematic depiction of how N-cadherin and NCAM, both cell adhesion molecules upregulated during malignant tumor progression, mediate proinvasive signaling. A, N-cadherin has several functions that may all contribute to tumor invasion and metastasis: First, cell-cell adhesion to N-cadherin-expressing cells of the stroma. Second, binding and activation of FGFR, which results in FGFR signaling and the promotion of cell survival, migration, and invasion. Third, cleavage and shedding of the extracellular domain of N-cadherin by ADAM metallopeptidase domain 10 (ADAM10). Shedded N-cadherin may neutralize N-cadherin-mediated cell-cell adhesion and/or stimulate FGFR signaling on neighboring cells. Fourth, cleavage of N-cadherin by  $\gamma$ -secretase results in the translocation of the COOH-terminal fragment of N-cadherin (CTF2) to the nucleus, where it binds CBP and induces its degradation, thus modulating CBP-mediated gene expression. B, NCAM expression is upregulated during EMT and associates with FGFRs outside of lipid rafts and with c-Fyn in lipid rafts to mediate sustained MAPK signaling resulting in focal adhesion assembly and cell migration. Low levels of NCAM form a complex with FGFR and PLC $\gamma$ , leading to the activation of the Raf-kinase PKC $\beta$ II and thus to sustained activation of the MAPK pathway and cell adhesion. Upon loss of E-cadherin function during EMT, NCAM is highly expressed, and a subset localizes to lipid rafts where it associates with p59<sup>Fyn</sup>, leading to focal adhesion kinase (FAK) phosphorylation, focal adhesion assembly, and cell migration. Both NCAM-mediated signaling pathways are required for cell migration and invasion. In contrast, FGF-induced stimulation of FGFR results in PLC $\gamma$ -mediated activation of PKC $\alpha$  and a short pulse activation of the Ras/Raf/MAPK pathway, resulting in cell adhesion and proliferation. FGF-induced signaling is overruled by NCAM-mediated signaling (adapted from ref. 24).

The tight regulation of actin cytoskeleton remodeling is not only critical for cell motility but also for other cellular processes, such as endocytosis and intracellular trafficking, and it seems meaningful that a direct link between endocytotic pathways, actin assembly, and cancer cell invasion has been established (119). Receptor tyrosine kinase-mediated mitogenic activation of Rac occurs at the endosome where the RacGEF Tiam1 is engaged. Rab5-dependent endocytosis is then required to localize Rac to the plasma membrane and to induce the formation of migratory actin protrusions. Such stepwise activation ensures a spatial regulation of Rac activity by the endosomal-recycling pathway and by the RacGEF Tiam1. Tight control of endocytosis in migrating cells is also required for the rapid recycling of  $\beta_1$ -integrin at pseudopodal membrane protrusions and the retention of a pool of  $\beta_1$ -integrin at the cell front by the GTPase Rab25 (120). Interestingly, mutant p53, as frequently found in malignant cancers, promotes the trafficking of  $\beta_1$ -integrin and of EGFR, resulting into increased  $\beta_1$ -integrin/EGFR signaling and cell invasion and metastasis (121).

As mentioned above, depending on the presence of epithelial or mesenchymal cadherins, the localization and function of p120-catenin and thus the activity of RhoGTPases change dramatically (122). In epithelial cells, p120-catenin localizes at the cell membrane and associates with E-cadherin where it controls the activity of RhoA and Rac1. RhoA activity, which is required for the initial cell-cell contact formation, is downregulated in established, mature cell adhesions. Both activation and inactivation of RhoA require the p120-catenin-dependent recruitment of RhoGEFs, like Vav2, or RhoGAPs, like p190-RhoGAP. The recruitment of p190-RhoGAP results in the activation of Rac1, which leads to the stabilization of E-cadherin junctions by inhibiting the activities of IQ-domain GAP1 (IQGAP1), a Rac1 effector protein, and a mediator of E-cadherin endocytosis (see also below). Moreover, the actin cytoskeleton underlying cell contacts is reorganized and stabilized (123).

Upon loss of E-cadherin in migrating cancer cells, p120-catenin binds to mesenchymal cadherins at the cell membrane, but is also found localized in the cytoplasm (Fig. 2B). Cytoplasmic p120-catenin functions as a RhoA-GDI that binds and represses RhoA activity (124). Simultaneously, p120-catenin bound to mesenchymal cadherins at the cell membrane promotes Rac1 activity and induces the formation of lamellipodia. Thus, both cytoplasmic and membrane-sequestered p120-catenin cooperate to induce cell motility during EMT. Interestingly, Rac1 inhibits RhoA activity by inducing the production of reactive oxygen species, which in turn activate p190RhoGAP by inhibiting low molecular weight protein tyrosine phosphatase (92, 125). Moreover, expression of Snail1 is increased upon reactive oxygen species production by Rac1b, a splice variant of Rac (126). The importance of RhoGTPases in tumor cell migration and malignant tumor progression is also underscored by the observation that Rac1b is highly expressed in malignant breast tissues and that cytoplasmic

p120-catenin together with RhoA downregulation correlates with poor prognosis in colorectal cancer (124).

The RacGEF Tiam1 also exerts a critical function in both E-cadherin-mediated cell-cell junction stability and during EMT. Loss of Tiam1 activity is required for the induction of EMT; forced expression of constitutive active forms of Rac1 (RacV12) or Tiam-1 prevents HGF-induced EMT in epithelial cells (127, 128). Conversely, Tiam1 is required for Rac1-mediated integrin-mediated laminin-5 deposition, cell spreading, and cell motility in keratinocytes (129). Interestingly, ablation of Tiam-1 in a mouse model of chemically induced skin carcinogenesis reduces tumor incidence but increases tumor malignancy, thus demonstrating an ambivalent role of Rac1 in tumor formation and tumor progression (130).

RhoC, a close family member of RhoA, has been previously identified as having a strong prometastatic activity (131). Indeed, although dispensable for development and postnatal life, ablation of RhoC function during mouse mammary carcinogenesis has no effect on primary tumor growth, yet decreases tumor cell motility and metastasis (132). Notably, miRNA10b, upregulated during EMT and tumor progression by the transcription factor Twist, has been found to repress the expression of the transcription factor HoxD10, which, in turn, represses RhoC expression (133). Supporting its prometastatic role, expression of RhoC correlates with high metastatic potential in oral squamous cell carcinoma, pancreatic adenocarcinoma, and inflammatory breast cancer (132, 134).

All the molecular pathways and regulatory circuits discussed above may be found in solitary migrating cells. However, based on morphologic and functional differences, single-cell migration has been distinguished into mesenchymal cell migration and amoeboid migration (1, 135). Either one or a mixture of both is found in cancer cells. Mesenchymal cell migration is exerted by spindle-shaped, fibroblast-like cells, such as fibroblasts, endothelial cells, smooth muscle cells, and cancer cells. It is characterized by cellular movements driven by a leading edge with Rac-induced cell protrusions and actin polymerization as cortical cables and stress fibers. These cells remodel the extracellular matrix by proteolysis and exhibit a slow turnover of  $\beta_1$ - and  $\beta_3$ -integrin-mediated focal adhesions and rather slow cell migration. In contrast, amoeboid cell migration is used by rounded cells, such as hematopoietic stem cells, leukocytes, and cancer cells, which in a push-and-squeeze type of migration make their way through the extracellular matrix. Their movement is driven by RhoA/ROCK-mediated bleb-like protrusions with active myosin/actin contractions and with cortical actin, yet a lack of stress fibers. The ECM is remodeled only by mechanical force in the absence of significant proteolytic activity. Non-integrin adhesion mechanisms rather than specific integrin-mediated focal adhesions are used, and thus no focal adhesion turnover is observed, and the cells migrate rather fast (106, 136, 137). However, the extent and type of collagen cross-linking seems to affect the requirement for proteolysis during amoeboid migration *in vitro*, and



MT1-MMP proteolytic activity seems indispensable for amoeboid migration in naturally cross-linked collagen *in vitro* and *in vivo* (135).

The molecular pathways underlying the differences between mesenchymal and amoeboid cell migration are just being elucidated. For example, a siRNA screen for RhoGEFs and RhoGAPs has revealed specificities in the activation of RhoA and Rac that directly affect mesenchymal and amoeboid migration (138). The RhoGEF Dock3 and the adaptor protein NEDD9 seem to be required for Rac activity and for elongated cell movement. Once activated, Rac represses phosphorylation of myosin light chain 2 through WAVE2, thus repressing amoeboid (Rho-mediated) movement. Conversely, activated RhoA signaling, through ROCK, activates the RacGAP ARHGAP22, thus suppressing Rac activity and with it mesenchymal motility. The amoeboid migration of A375 melanoma cells in three-dimensional matrix also depends on ROCK-mediated actin-myosin contraction (139). Here, an independent siRNA screen has revealed that phosphoinositide-dependent protein kinase 1 (PDK1), as protein and not as kinase activity, is required together with RhoA-GTP to localize ROCK-I to the plasma membrane, which results in phosphorylation of myosin light chain and cell motility. PDK1 directly competes with RhoE for binding ROCK-I, thereby overcoming the negative regulation by RhoE. These experiments link phosphoinositide 3-kinase signaling and RhoA activity through a noncatalytic function of PDK1. Tightly controlled remodeling of the actin cytoskeleton also plays a critical role in defining the mode of cell motility. For example, ablation of cofilin function converts amoeboid migrating cancer cells into mesenchymal-type cells (140). These experimental results exemplify the large plasticity of solitary cancer cells in selecting different types of invasive migration.

## Collective Invasion

In contrast to the various types of solitary migration, collectively migrating cells maintain their cell-cell junctions and migrate in sheets, strands, tubes, and clusters, either still in connection with their originating tissue or as separated, independently migrating clusters (2, 141). On a cellular level, there are only few differences to solitary migrating cells. Collectively migrating cells also form membrane protrusions, such as ruffles and pseudopodes; they use cell-matrix adhesion receptors, such as  $\beta_1$ -integrin and  $\beta_3$ -integrin, to form focal adhesions connected to the actin cytoskeleton; they direct proteolytic breakdown of the extracellular matrix to generate a path through the matrix scaffold; and they use the actin-myosin contractile apparatus for local contraction and cell movement. Yet, in contrast to their solitary migrating counterparts, collectively migrating cells do not retract their cellular tails but rather exert pulling forces on neighboring cells that are connected by adhesion junctions. Thereby, cells keep in most, but not all, cases their position in the collective

structures, such as in two-dimensional sheets and in three-dimensional solid strands.

Collective migration is used during many developmental morphogenic processes, in which cells move in groups, with tight or loose association between each other and with protrusions that distinguish actively and directionally migrating cells from their neighboring followers. Such combination of cell migration and cell adhesion requires a fine-tuned crosstalk between cell-cell adhesion and cell contractility (142, 143). Examples are the morphogenic movement of cells of the inner blastocyst, converging extension of the vertebrate embryo, and closure of the dorsal surface and trachea morphogenesis in the *Drosophila* embryo. In zebrafish, the cells forming the prospective lateral midline represent a migrating group of cells in the absence of any EMT. Also, mammary branching morphogenesis, vascular sprouts during angiogenesis, and keratinocytes migrating across the wound matrix are typical examples of collective cell migration in sheets, tubes, or cell clusters (2). Depending on the species, the process of gastrulation exhibits a mixture of collective cell migration and cells that have undergone EMT, also indicating that the borders between single-cell migration and collective migration are murky.

Collective cell migration has been best studied in migrating border cells of the *Drosophila* oocyte. These cells migrate as cohorts between nurse cells toward the oocyte. This migration is dependent on myosinVI and E-cadherin, wherein myosinVI stabilizes E-cadherin adhesion complexes (144). Yet, excessive adhesion, for example, caused by a mutation in the gene *Hindsight*, prevents collective migration. The mammalian homologue of *Hindsight*, *RREB*, is also required for mammary epithelial tubular morphogenesis. It is essential for regulating the dynamic changes in cell-cell adhesion required during collective migration (145). Border cell cluster integrity and adhesion plasticity is regulated by Jun-kinase-mediated signal transduction, which also affects the polarity factor Bazooka and the cytoskeletal adaptor Paxillin, thus functionally connecting cell adhesion, cell polarity, and cell migration (143, 146).

In cancer, collective cell migration and invasion is found in distinct cancer types, including high and intermediate differentiated types of lobular breast cancer, epithelial prostate cancer, large cell lung cancer, melanoma, rhabdomyosarcoma, and most prominently in squamous cell carcinoma. Invading cells of these cancers form cone- or finger-like fronts and intravasate and disseminate as cell clusters, a form of metastatic dissemination that seems to be highly efficient in embolizing lymphatic or blood vessels and in surviving circulation (147).

To penetrate the extracellular matrix as a cell collective, the leading cells generate an invasion path. High-resolution multimodal microscopy has shown that the guiding cells use  $\beta_1$ -integrin-mediated focal adhesions and local expression of MT1-MMP at their leading edges to cleave collagen fibers and orient them in a way that generates tube-like microtracks into which the collective mass migration of follower cells can occur (137, 148). Thus, similar to single-cell migration, invasive migration and proteolytic

matrix remodeling are interdependent processes that also control collective cell migration.

Insights into the molecular regulation of collective cell migration have also been obtained by investigating the expression of the cell surface glycoprotein podoplanin (T1 $\alpha$ -2, aggrus, gp36), a 38 kDa, type-I sialo-mucine-like transmembrane glycoprotein, expressed in a variety of cell types, including kidney podocytes, alveolar type I cells, lymphatic endothelial cells, platelets, and several other cell types (149). Podoplanin is also expressed in a number of different cancer types, including squamous cell carcinoma of the oral cavity, larynx, lung, cervix, esophagus, and skin, in dysgerminomas of the ovary, in granulosa cell tumors, in testicular germ cell tumors, in mesothelioma, in a subset of lobular breast cancers, and in tumors of the central nervous system (19, 149, 150). Most of these cancer types, in particular squamous cell carcinoma, are well known to exhibit cone- or finger-like collective invasion into neighboring tissue. Notably, in most of these cancer types, podoplanin expression is mainly confined to the outer cell layer of the invading tumor front.

Forced expression of podoplanin in human keratinocytes and in MCF7 breast cancer cells induces cell migration and invasion with a significant decrease of cellular stress fibers and a concomitant formation of filopodia-like membrane protrusions, even in the presence of E-cadherin expression (19, 151). Podoplanin-expressing A431 squamous cell carcinoma cells exhibit higher tumorigenicity and, similar to the expression in squamous cell carcinomas of patients, exhibit collective invasion and express podoplanin in the outer cell layer of the invading front when transplanted into mice (152). Moreover, transgenic expression of podoplanin in tumor cells of the Rip1Tag2 mouse model of pancreatic  $\beta$ -cell carcinogenesis leads to the formation of invasive carcinomas in the absence of a cadherin switch and EMT (19). Thus, podoplanin seems to shift the invasion pattern from single-cell invasion involving EMT to collective invasion in the absence of EMT.

In contrast, expression of podoplanin in Madin-Darby canine kidney cells induces cell motility and invasion in the presence of full EMT with a loss of E-cadherin expression and the gain of N-cadherin expression (153). This activity is dependent on the short COOH-terminal domain through which podoplanin physically associates with ezrin and moesin but not radixin. This interaction results in an elevation of RhoA GTPase activity, and both ezrin and RhoA function are required for podoplanin-induced EMT. In addition, overexpression of podoplanin in Madin-Darby canine kidney cells and also MCF7 cells leads to a marked increase in phosphorylation of ezrin in a RhoA-dependent manner (19, 153). Thus, ERM proteins may link podoplanin expression to the observed rearrangement of the actin cytoskeleton. Recently, p120-catenin has also been implicated in the functional connection between collective cell migration and the maintenance of E-cadherin-mediated adherens junctions (154). Ablation of p120-catenin in A431 squamous cell carcinoma cells results in the loss of three-dimensional, collective invasion induced

by EGF, which depends on the membrane localization of p120-catenin and on intact E- or P-cadherin-mediated cell-cell adhesion. However, the detailed mechanism of how podoplanin mediates collective cell migration remains to be elucidated.

Besides using cell-autonomous mechanisms, collectively migrating cancer cells may also rely on the support of stromal cells to pave their way through the extracellular matrix. Indeed, leader cells are identifiable in culture experiments, with distinct morphology, highly polarized cell shape, and the formation of lamellipodia (155). These leader cells are connected by E-cadherin-mediated junctions to their neighboring cells, and when dragging their neighbors, holes forming in the migrating cell mass are filled by cell proliferation. Moreover, in coculturing experiments between carcinoma cells and stromal fibroblasts, the fibroblasts lead the migrating carcinoma cells and prepare migratory tracks by proteolytic digestion and by force-mediated remodeling of the matrix (156). This process involves Rho-mediated myosin light chain activity in fibroblasts and the activities of Cdc42 and myotonic dystrophy kinase-related CDC42-binding protein kinase in carcinoma cells. Such stromal support seems required for epithelial cells that are retaining their epithelial organization. In contrast, collectively migrating highly invasive carcinoma cells (that have undergone EMT) or mesenchymal sarcoma cells are able to digest their way through the matrix without any support by stromal cells (137).

These clinical and experimental observations underscore the importance of collective cell migration in malignant tumor progression. However, the regulatory pathways underlying collective cell migration have just begun to be elucidated and its clinical manifestations, prognostic value, and actual contribution to metastasis remain to be assessed.

## Conclusions/Perspectives

Cancer cell migration and invasion are certainly critical processes in the metastatic cascade. They can be induced and executed by various signaling pathways and regulatory networks. Many of these pathways seem to overlap with developmental processes and are being abused by cancer cells and the tumor microenvironment. Yet, although we have made substantial progress in the understanding of the molecular mechanisms underlying cancer cell migration and invasion in experimental systems, we still lack sufficient insights into the actual processes at work in cancer patients. This divergence between clinicopathologic and experimental observations is mainly based on the lack of appropriate surrogate markers and the lack of complex *in vivo* models that appropriately recapitulate human stochastic carcinogenesis. However, it is likely that the ongoing cell biological research on cell migration will provide the urgently needed tools for the development of improved diagnosis and prognosis and eventually for the design of innovative therapies.

Only few therapeutic approaches that are currently in development or in clinical trials specifically target cancer

cell migration, such as interfering with integrin functions of invasive cancer cells. However, by interfering with important signaling pathways that are known to modulate cell proliferation, survival, and differentiation, they may also affect cell migration and invasion. Examples are inhibitors against the activities of different receptor tyrosine kinases, such as EGFR, IGF1R, c-Met/HGF receptor, PDGFR, and FGFR, as well as various antiangiogenesis regimen or even combinations thereof. Altogether, such multifaceted inhibitory approaches may provide efficient therapeutic measures that repress not only primary tumor outgrowth but also metastasis formation by interfering with cancer cell migration and invasion. However, the cellular and molecular variations to cancer cell migration discussed above raise the caveat that this endeavor will not be easy.

## References

- Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. *J Cell Biol* 2010;188:11–9.
- Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. *Nat Rev Mol Cell Biol* 2009;10:445–57.
- Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer* 2009;9:239–52.
- Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer* 2009;9:285–93.
- Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. *Nat Rev Cancer* 2007;7:429–40.
- Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. *Clin Exp Metastasis* 2008;26:273–87.
- Gupton SL, Gertler FB. Filopodia: the fingers that do the walking. *Sci STKE* 2007;2007:re5.
- Vignjevic D, Montagnac G. Reorganisation of the dendritic actin network during cancer cell migration and invasion. *Semin Cancer Biol* 2008;18:12–22.
- Guo W, Giancotti FG. Integrin signalling during tumour progression. *Nat Rev Mol Cell Biol* 2004;5:816–26.
- Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. *Cancer Metastasis Rev* 2009;28:65–76.
- Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. *Cancer Metastasis Rev* 2009;28:35–49.
- Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 2006;7:131–42.
- Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. *Nat Rev Mol Cell Biol* 2003;4:657–65.
- Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* 2009;9:265–73.
- Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res* 2008;68:989–97.
- Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and  $\beta$ -catenin. *Cells Tissues Organs* 2005;179:56–65.
- Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. *Cancer Res* 2005;65:5996–6000; discussion 6000–1.
- Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. *Curr Opin Cell Biol* 2004;16:14–23.
- Wicki A, Lehenbre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* 2006;9:261–72.
- Cavallaro U. N-cadherin as an invasion promoter: a novel target for antitumor therapy? *Curr Opin Investig Drugs* 2004;5:1274–8.
- Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. *J Cell Sci* 2008;121:727–35.
- Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. *Nat Rev Cancer* 2004;4:118–32.
- Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature* 1998;392:190–3.
- Lehenbre F, Yilmaz M, Wicki A, et al. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. *EMBO J* 2008;27:2603–15.
- Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res* 2008;68:3645–54.
- Bissell MJ, Radisky D. Putting tumours in context. *Nat Rev Cancer* 2001;1:46–54.
- Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. *Nat Rev Cancer* 2004;4:177–83.
- Zavadil J, Bottlinger EP. TGF- $\beta$  and epithelial-to-mesenchymal transitions. *Oncogene* 2005;24:5764–74.
- Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. *J Cell Biol* 1997;137:1403–19.
- Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. *Cancer Res* 2007;67:9066–76.
- Graham TR, Zhou HE, Odeiro-Marrah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. *Cancer Res* 2008;68:2479–88.
- Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. *J Cell Biol* 2006;172:973–81.
- Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. *Cancer Cell* 2007;12:559–71.
- Leong KG, Niessen K, Kulic I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. *J Exp Med* 2007;204:2935–48.
- Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S,

- Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell* 2003;3:347–61.
36. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. *Nature* 2003;425:307–11.
  37. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nat Rev Cancer* 2007;7:415–28.
  38. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* 2008;10:593–601.
  39. Korpala M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem* 2008;283:14910–4.
  40. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. *EMBO Rep* 2008;9:582–9.
  41. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* 2008;22:894–907.
  42. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nat Cell Biol* 2009;11:1487–95.
  43. Herranz N, Pasini D, Diaz VM, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. *Mol Cell Biol* 2008;28:4772–81.
  44. Hou Z, Peng H, Ayyanathan K, et al. The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. *Mol Cell Biol* 2008;28:3198–207.
  45. Berger SL. The complex language of chromatin regulation during transcription. *Nature* 2007;447:407–12.
  46. Yang X, Pursell B, Lu S, Chang TK, Mercurio AM. Regulation of  $\beta_4$ -integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. *J Cell Sci* 2009;122:2473–80.
  47. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol* 2010;12:247–56.
  48. Zhu W, Leber B, Andrews DW. Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. *EMBO J* 2001;20:5999–6007.
  49. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. *J Cell Biol* 1997;139:1861–72.
  50. Marambaud P, Shioi J, Serban G, et al. A presenilin-1/ $\gamma$ -secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. *EMBO J* 2002;21:1948–56.
  51. Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and  $\beta$ -catenin translocation. *Proc Natl Acad Sci U S A* 2005;102:9182–7.
  52. Steinhilber U, Weiske J, Badock V, Tauber R, Bommert K, Huber O. Cleavage and shedding of E-cadherin after induction of apoptosis. *J Biol Chem* 2001;276:4972–80.
  53. Ryniers F, Stove C, Goethals M, et al. Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. *Biol Chem* 2002;383:159–65.
  54. Ferber EC, Kajita M, Wadlow A, et al. A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. *J Biol Chem* 2008;283:12691–700.
  55. Gumbiner BM. Regulation of cadherin adhesive activity. *J Cell Biol* 2000;148:399–404.
  56. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. *Nat Cell Biol* 2002;4:222–31.
  57. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. *Cancer Res* 2006;66:4662–71.
  58. Janda E, Nevelo M, Lehmann K, Downward J, Beug H, Grieco M. Raf plus TGF $\beta$ -dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. *Oncogene* 2006;25:7117–30.
  59. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of  $\beta$ -catenin, and enhanced tumor cell invasion. *Cancer Cell* 2003;4:499–515.
  60. Akhtar N, Hotchin NA. RAC1 regulates adherens junctions through endocytosis of E-cadherin. *Mol Biol Cell* 2001;12:847–62.
  61. Morishige M, Hashimoto S, Ogawa E, et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. *Nat Cell Biol* 2008;10:85–92.
  62. Dunphy JL, Moravec R, Ly K, Lasell TK, Melancon P, Casanova JE. The Arf6 GEF GEP100/BRAG2 regulates cell adhesion by controlling endocytosis of  $\beta_1$  integrins. *Curr Biol* 2006;16:315–20.
  63. Kon S, Tanabe K, Watanabe T, Sabe H, Satake M. Clathrin dependent endocytosis of E-cadherin is regulated by the Arf6GAP isoform SMAP1. *Exp Cell Res* 2008;314:1415–28.
  64. Clevers H. Wnt/ $\beta$ -catenin signaling in development and disease. *Cell* 2006;127:469–80.
  65. Polakis P. The many ways of Wnt in cancer. *Curr Opin Genet Dev* 2007;17:45–51.
  66. Reya T, Clevers H. Wnt signalling in stem cells and cancer. *Nature* 2005;434:843–50.
  67. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. *Oncogene* 2006;25:7492–504.
  68. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. *J Cell Biol* 2006;174:863–75.
  69. Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of  $\beta$ -catenin-TCF signaling, is expressed at the invasive front of human colon cancer. *Cancer Res* 2007;67:6844–53.
  70. Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of  $\beta$ -catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. *J Cell Biol* 2005;168:633–42.
  71. Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G. Tumor progression induced by the loss of E-cadherin independent of  $\beta$ -catenin/Tcf-mediated Wnt signaling. *Oncogene* 2007;26:2290–8.
  72. Stehbens SJ, Paterson AD, Crampton MS, et al. Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts. *J Cell Sci* 2006;119:1801–11.
  73. Ireton RC, Davis MA, van Hengel J, et al. A novel role for p120 catenin in E-cadherin function. *J Cell Biol* 2002;159:465–76.
  74. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. *J Cell Biol* 2003;163:525–34.
  75. Thoreson MA, Anastasiadis PZ, Daniel JM, et al. Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. *J Cell Biol* 2000;148:189–202.
  76. Wildenberg GA, Dohn MR, Carnahan RH, et al. p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. *Cell* 2006;127:1027–39.
  77. Noren NK, Niessen CM, Gumbiner BM, Burridge K. Cadherin engagement regulates Rho family GTPases. *J Biol Chem* 2001;276:33305–8.
  78. Noren NK, Liu BP, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. *J Cell Biol* 2000;150:567–80.
  79. Boguslavsky S, Grosheva I, Landau E, et al. p120 catenin regulates lamellipodial dynamics and cell adhesion in cooperation with cactin. *Proc Natl Acad Sci U S A* 2007;104:10882–7.
  80. van Roy FM, McCrean PD. A role for Kaiso-p120ctn complexes in cancer? *Nat Rev Cancer* 2005;5:956–64.
  81. Lopes EC, Valls E, Figueroa ME, et al. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. *Cancer Res* 2008;68:7258–63.
  82. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. *J Cell Biol* 1999;147:631–44.
  83. Hult J, Suyama K, Chung S, et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. *Cancer Res* 2007;67:3106–16.

84. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. *Clin Cancer Res* 2007;13:7003–11.
85. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. *Ann N Y Acad Sci* 2004;1014:155–63.
86. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. *Cancer Res* 2006;66:3365–9.
87. Yang Z, Zhang X, Gang H, et al. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. *Biochem Biophys Res Commun* 2007;358:925–30.
88. Bard L, Boscher C, Lambert M, Mege RM, Choquet D, Thoumine O. A molecular clutch between the actin flow and N-cadherin adhesions drives growth cone migration. *J Neurosci* 2008;28:5879–90.
89. Theisen CS, Wahl JKR, Johnson KR, Wheelock MJ. NHERF links the N-cadherin/catenin complex to the platelet-derived growth factor receptor to modulate the actin cytoskeleton and regulate cell motility. *Mol Biol Cell* 2007;18:1220–32.
90. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. *Biochim Biophys Acta* 1998;1378: F79–113.
91. Kong D, Wang Z, Sarkar SH, et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. *Stem Cells* 2008;26:1425–35.
92. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. *J Cell Biol* 1999;147:1009–22.
93. Pertz O, Hodgson L, Klemke RL, Hahn KM. Spatiotemporal dynamics of RhoA activity in migrating cells. *Nature* 2006;440:1069–72.
94. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* 1992;70:401–10.
95. Nimnual AS, Taylor LJ, Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. *Nat Cell Biol* 2003;5:236–41.
96. Anastasiadis PZ, Moon SY, Thoreson MA, et al. Inhibition of RhoA by p120 catenin. *Nat Cell Biol* 2000;2:637–44.
97. Williams EJ, Williams G, Howell FV, Skaper SD, Walsh FS, Doherty P. Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. *J Biol Chem* 2001;276:43879–86.
98. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. *J Cell Biol* 2000;148: 779–90.
99. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. *Cancer Cell* 2002;2:301–14.
100. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. *Nat Cell Biol* 2001;3:650–7.
101. Francavilla C, Loeffler S, Piccini D, Kren A, Christofori G, Cavallaro U. Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. *J Cell Sci* 2007;120:4388–94.
102. Francavilla C, Cattaneo P, Berezin V, et al. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. *J Cell Biol* 2009;187:1101–16.
103. Marambaud P, Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. *Cell* 2003;114:635–45.
104. Shoval I, Ludwig A, Kalcheim C. Antagonistic roles of full-length N-cadherin and its soluble BMP cleavage product in neural crest delamination. *Development* 2007;134:491–501.
105. Uemura K, Kihara T, Kuzuya A, et al. Activity-dependent regulation of  $\beta$ -catenin via epsilon-cleavage of N-cadherin. *Biochem Biophys Res Commun* 2006;345:951–8.
106. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat Rev Cancer* 2003;3:362–74.
107. Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. *Cancer Metastasis Rev* 2009;28:137–49.
108. Valderrama F, Ridley AJ. Getting invasive with GEP100 and Arf6. *Nat Cell Biol* 2008;10:16–8.
109. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. *FEBS Lett* 2008;582:2093–101.
110. Sahai E, Marshall CJ. RHO-GTPases and cancer. *Nat Rev Cancer* 2002;2:133–42.
111. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. *Annu Rev Cell Dev Biol* 2005;21:247–69.
112. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. *Nature* 2002;420:629–35.
113. Burridge K, Wennerberg K. Rho and Rac take center stage. *Cell* 2004;116:167–79.
114. Hall A. Rho GTPases and the control of cell behaviour. *Biochem Soc Trans* 2005;33:891–5.
115. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. *Trends Cell Biol* 2006;16:522–9.
116. Lozano E, Betson M, Braga VM. Tumor progression: Small GTPases and loss of cell-cell adhesion. *BioEssays* 2003;25: 452–63.
117. Cavey M, Rauzi M, Lenne PF, Lecuit T. A two-tiered mechanism for stabilization and immobilization of E-cadherin. *Nature* 2008;453: 751–6.
118. Sahai E. Illuminating the metastatic process. *Nat Rev Cancer* 2007; 7:737–49.
119. Palamidessi A, Frittoli E, Garre M, et al. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. *Cell* 2008;134:135–47.
120. Caswell PT, Spence HJ, Parsons M, et al. Rab25 associates with  $\alpha_5\beta_1$  integrin to promote invasive migration in 3D microenvironments. *Dev Cell* 2007;13:496–510.
121. Muller PA, Caswell PT, Doyle B, et al. Mutant p53 drives invasion by promoting integrin recycling. *Cell* 2009;139:1327–41.
122. Cozzolino M, Stagni V, Spinardi L, et al. p120 catenin is required for growth factor-dependent cell motility and scattering in epithelial cells. *Mol Biol Cell* 2003;14:1964–77.
123. Anastasiadis PZ. p120-ctn: a nexus for contextual signaling via Rho GTPases. *Biochim Biophys Acta* 2007;1773:34–46.
124. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. *Cancer Res* 2005;65:10938–45.
125. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. *J Cell Biol* 2000;149:775–82.
126. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. *Nature* 2005;436:123–7.
127. Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LC, Collard JG. Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. *Science* 1997;278:1464–6.
128. Malliri A, van Es S, Huveneres S, Collard JG. The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions. *J Biol Chem* 2004;279:30092–8.
129. Hamelers IH, Olivo C, Mertens AE, et al. The Rac activator Tiam1 is required for  $(\alpha)3(\beta)1$ -mediated laminin-5 deposition, cell spreading, and cell migration. *J Cell Biol* 2005;171:871–81.
130. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. *Nature* 2002;417:867–71.
131. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. *Nature* 2000;406: 532–5.
132. Hakem A, Sanchez-Sweetman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. *Genes Dev* 2005;19:1974–9.
133. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007; 449:682–8.

134. Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. *Clin Cancer Res* 2006;12:4485–90.
135. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus-independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. *J Cell Biol* 2009;185:11–9.
136. Wolf K, Muller R, Borgmann S, Bocker EB, Friedl P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. *Blood* 2003;102:3262–9.
137. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. *Nat Cell Biol* 2007;9:893–904.
138. Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. *Cell* 2008;135:510–23.
139. Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. *Nat Cell Biol* 2008;10:127–37.
140. Sidani M, Wessels D, Mouneimne G, et al. Cofilin determines the migration behavior and turning frequency of metastatic cancer cells. *J Cell Biol* 2007;179:777–91.
141. Friedl P, Hegerfeldt Y, Tusch M. Collective cell migration in morphogenesis and cancer. *Int J Dev Biol* 2004;48:441–9.
142. Rorth P. Collective guidance of collective cell migration. *Trends Cell Biol* 2007;17:575–9.
143. Montell DJ. Morphogenetic cell movements: diversity from modular mechanical properties. *Science* 2008;322:1502–5.
144. Geisbrecht ER, Montell DJ. Myosin VI is required for E-cadherin-mediated border cell migration. *Nat Cell Biol* 2002;4:616–20.
145. Melani M, Simpson KJ, Brugge JS, Montell D. Regulation of cell adhesion and collective cell migration by hindsight and its human homolog RREB1. *Curr Biol* 2008;18:532–7.
146. Llense F, Martin-Blanco E. JNK signaling controls border cell cluster integrity and collective cell migration. *Curr Biol* 2008;18:538–44.
147. Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. *Eur J Cancer* 1973;9:223–7.
148. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. *Cancer Res* 2008;68:7247–9.
149. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. *Br J Cancer* 2007;96:1–5.
150. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. *Am J Pathol* 2005;166:913–21.
151. Scholl FG, Gamallo C, Vilaro S, Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. *J Cell Sci* 1999;112:4601–13.
152. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. *Biochem Biophys Res Commun* 2008;373:36–41.
153. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. *J Cell Sci* 2006;119:4541–53.
154. Macpherson IR, Hooper S, Serrels A, et al. p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. *Oncogene* 2007;26:5214–28.
155. Poujade M, Grasland-Mongrain E, Hertzog A, et al. Collective migration of an epithelial monolayer in response to a model wound. *Proc Natl Acad Sci U S A* 2007;104:15988–93.
156. Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat Cell Biol* 2007;9:1392–400.

# Molecular Cancer Research

## Mechanisms of Motility in Metastasizing Cells

Mahmut Yilmaz and Gerhard Christofori

*Mol Cancer Res* 2010;8:629-642. Published OnlineFirst May 11, 2010.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1541-7786.MCR-10-0139](https://doi.org/10.1158/1541-7786.MCR-10-0139)

**Cited articles** This article cites 156 articles, 64 of which you can access for free at:  
<http://mcr.aacrjournals.org/content/8/5/629.full#ref-list-1>

**Citing articles** This article has been cited by 27 HighWire-hosted articles. Access the articles at:  
<http://mcr.aacrjournals.org/content/8/5/629.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://mcr.aacrjournals.org/content/8/5/629>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.